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Objective: MicroRNAs (miRNAs) are used as biomarkers in cardiovascular disease
and cancer. miRNAs are involved in placental development but have not previously
been investigated in twin‐twin transfusion syndrome (TTTS). Our aim is to explore
the miRNA profile of TTTS pregnancies.
Method: Initial miRNA profiling was performed using a reverse transcription poly-
merase chain reaction (RT‐PCR) panel on maternal serum samples taken from five
women prior to fetoscopic laser ablation for TTTS and compared with serum samples
from five women with uncomplicated monochorionic diamniotic twin pregnancies.
Validation RT‐PCR was performed in an additional cohort of eight TTTS pregnancies
and eight uncomplicated pregnancies.
Results: Median gestational age at sampling in the TTTS and control groups was
20+0 weeks (interquartile range [IQR], 19+4‐20+0) and 20+2 weeks (IQR, 20+0‐20+2),
respectively. All samples passed quality control. One control sample was excluded
as a biological outlier. Thirty‐one of 752 miRNAs were significantly different: 17 were
upregulated and 14 downregulated in the TTTS group, although they did not remain
significant following Benjamini‐Hochberg correction for multiple testing. The six
miRNAs chosen for validation demonstrated no significant difference.
Conclusion: This is the first study to investigate miRNA changes in TTTS pregnan-
cies. We did not demonstrate a statistically significant difference in miRNAs in TTTS
pregnancies, but further investigation is required.1 | INTRODUCTION
Twin‐twin transfusion syndrome (TTTS) complicates up to 15% of
monochorionic diamniotic (MCDA) twins and if untreated is associated
with a perinatal mortality of 80% to 90%1 and significant- - - - - - - - - - - - - - - - - - - - - - - - - -
Creative Commons Attribution Li
by John Wiley & Sons Ltdneurodevelopmental morbidity.2 The “donor” is hypoperfused and
hypotensive with associated poor urine output and oligohydramnios,
while the “recipient” has a hyperdynamic circulation, polyuria, and
polyhydramnios with a high prevalence of cardiac dysfunction.3,4 TTTS
is associated with chronic unidirectional intertwin blood flow through- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cense, which permits use, distribution and reproduction in any medium, provided
Prenatal Diagnosis. 2019;39:616–634.
What's already known about this topic?
• Twin‐twin transfusion syndrome (TTTS) is a common
complication of monochorionic twins associated with
high perinatal mortality and morbidity if untreated.
• TTTS has its origins in the monochorionic placenta with
“conjoining” of the twin fetal circulations by anastomoses.
• Screening for TTTS relies upon regular, sequential
ultrasound examination of the pregnancy observing for
amniotic fluid discordance.
• MicroRNAs have been implicated in pregnancy‐related
placental disease and may act as potential biomarkers in
pregnancy complications.
What does this study add?
• This is the first study to explore microRNAs in TTTS. In
maternal serum, the six microRNAs that were validated did
not demonstrate a statistically significant difference in
pregnancies complicated by TTTS, compared with
uncomplicatedmonochorionic diamniotic twin pregnancies.
• Further investigation into the potential role of
microRNAs in TTTS is warranted, particularly in different
tissue samples.
MACKIE ET AL. 617monochorionic placental arteriovenous anastomoses (AVAs) leading to
the hemodynamic imbalance within the twin fetal circulations.5
Presently, screening for TTTS involves the use of serial ultrasound,
primarily to detect an imbalance of amniotic fluid in the
monochorionic twins.6 Such ultrasound screening is workforce inten-
sive, and a high proportion of MCDA twin pregnancies will not
develop TTTS or growth restriction but will still undergo ultrasound
screening every 2 weeks throughout pregnancy. However, timely
detection of TTTS allows treatment by fetoscopic laser ablation
(FLA) of the placental vascular anastomoses with a potential to modify
the underlying disease process and significantly improve outcome.7
The theoretical use of maternal circulating biomarkers in screening
for TTTS in its preclinical state and aiding in the definition of adverse
pregnancy outcome in a monochorionic twin pregnancy would be ben-
eficial, either alone or in combination with ultrasound findings.8,9
MicroRNAs (miRNAs) are highly ubiquitous noncoding RNAs,
consisting of a single strand of around 21 to 25 nucleotides that are
conserved across many species.10 They are involved in posttranscrip-
tional regulation of gene expression and function through base‐pairing
with the 3′ untranslated region (UTR) of the complementary messenger
RNA (mRNA) molecules, which then silences the mRNA by degradation
of the target mRNA, or repression of translation.11,12 These endoge-
nous regulatory miRNAs are present in many human bodily fluids and
tissues, including the human placenta.13-19 Their potential role as bio-
markers in detecting and defining prognosis in heart disease and cancer
has been reported,20 although there is less miRNA research in preg-
nancy, particularly twin pregnancy. In pregnancy, miRNAs appear
important in human placentation affecting trophoblast proliferation,
angiogenesis, and fetal growth.21,22 Placental miRNA is known to be
present, and stable, in maternal plasma23 and is believed to be released
from the syncytiotrophoblast and carried in the plasma in at least two
forms: protein‐bound miRNA and vesicular miRNA.24 They are cleared
from the maternal circulation soon after delivery.25 Previous studies
have demonstrated miRNA changes in maternal plasma in preeclamp-
sia,26-34 in miRNAs thought to be related to angiogenesis. Indeed, cer-
tain miRNAs (miR‐195‐5p) may be linked to the increase in sFLT‐1
seen in preeclamptic pregnancies.35 Thus, miRNAs may act as “bio-
markers” of placental and vascular function in pregnancy. There have
been no previous reports of miRNAs inTTTS pregnancies. We hypoth-
esized that there was a difference in human maternal serum miRNAs in
pregnancies complicated with TTTS compared with uncomplicated
matched MCDA twin pregnancies and that there is the potential for
these molecules to be used as “biomarkers” of disease.2 | METHODS
2.1 | Patients
Patients were recruited prospectively as part of the Optimal
Management of Monochorionic Twins (OMMIT) study into an
“investigation” or “validation” cohort.8 Briefly, maternal blood samples
were obtained the day prior to FLA from patients attending the WestMidlands Fetal Medicine Centre for FLA for the treatment of TTTS
from August 2015 to August 2017. TTTS was defined as a maximum
pool depth (MPD) > 8 cm in the recipient twin at less than 20 weeks
gestation, or MPD >10 cm at greater than 20 weeks gestation, in com-
bination with a MPD < 2 cm in the donor twin. Patients were prospec-
tively staged using the Quintero classification.36 A control group of
pregnant women with uncomplicated MCDA twin pregnancies who
booked at BirminghamWomen's and Children's NHS FoundationTrust
were recruited over the same time period for the investigation work
and validation work. Women were only included once chorionicity
was confirmed by the presence of the “T” sign on first trimester ultra-
sound.37 Women whose pregnancies were affected by chromosomal/
structural anomalies were not eligible for inclusion. Participants in the
control group had no serious adverse maternal or fetal outcome and
delivered two healthy babies, which did not require neonatal unit
admission. Patients were matched based on maternal age, ethnicity,
parity, body mass index (BMI), gestation at blood sampling, and fetal
sex. This study received ethical approval from East Midlands Research
Ethics Committee (15/EM/0244) in 2015, and all patients provided
written informed consent.2.2 | Blood samples
Venous blood samples were collected in 7.5‐mL serum gel tubes
(Sarstedt, Nümbrecht, Germany) from the antecubital fossa, allowed
618 MACKIE ET AL.to clot for 1 hour at room temperature, centrifuged at 3000 g for
10 minutes at room temperature, and sediment‐free serum aliquots
were stored immediately at −80°C prior to analysis and during transit.
Serum sample aliquots were stored for a maximum of 13 months prior
to analysis, which is considered acceptable practice in a recent best
practice paper.382.3 | Investigation profiling array
Samples taken from women in the investigation cohort were used to
perform the initial investigation profiling array.2.4 | RNA extraction
Total RNAwas extracted from serum using themiRCURYRNA Isolation
Kit—Biofluids (Exiqon, Vedbaek, Denmark) as per the manufacturer's
instructions (See Appendix A). The extracted RNA was stored at
−80°C prior to transfer to Exiqon, Denmark, 2 months later, on dry ice.2.5 | Quality control assessment of samples
Hemolysis was assessed by two miRNAs known to correlate with the
degree of hemolysis: hsa‐miRNA‐451, which is expressed on red blood
cells, and hsa‐miRNA‐23a, which is not affected by hemolysis. A
ratio > 7.0 of those two miRNAs indicates that the sample may be
affected by hemolysis. Spike‐in (RNA isolation control UniSp2, UniSp4,
UniSp5, and cDNA synthesis control UniSp6) was added to each sam-
ple as technical controls to assess extraction, reverse transcription,
and qPCR. A negative control, “no template” sample, was included in
the reverse transcription step to detect RNA contamination.2.6 | Quantitative real‐time polymerase chain
reaction for miRNAs
miRNA profiling was performed by Exiqon using the miRCURY LNA
Universal RT microRNA PCR Human panel I + II. These panels contain
primer sets for the 752 human miRNA most commonly differentially
expressed in disease and/or cited in the scientific literature, including
miRNAs associated with cardiovascular disease, renal disease, angio-
genesis, and placenta‐specific miRNA, in‐keeping with the pathophys-
iological mechanisms of TTTS (see Appendix B for full list of miRNAs
tested). All the miRNAs were polyadenylated and reverse transcribed
into cDNA. The cDNA and ExiLENT SYBR Green master mix were
transferred to the qPCR panels with 384‐well plates preloaded with
the specified primers, using a pipetting robot. The amplification was
performed in a Lightcycler 480 Instrument (Roche).2.7 | Validation with RT‐PCR of candidate miRNAs
From the initial profiling array, eight candidate miRNAs were identified
for validation based on being significantly different in the TTTS com-
pared with control samples, prior to Benjamini‐Hochberg correctionfor multiple testing; being present in all investigation cohort samples;
having validated targeted functional genes with strong evidence of
miRNA‐target interaction (MTI) reported on MiRTarBase (version
7.0)39; and biological plausibility for association with TTTS based on a
literature search using keywords: placenta, pregnancy, twin, maternal,
gestation, cardio‐$, renal‐$, vascul‐$, angio‐$, trophoblast, and fetal.
miRNA was extracted from serum with miRNeasy Serum/Plasma
Kit (Qiagen, Manchester, UK) according to manufacturer's instructions.
The quality and the concentration of the samples were investigated
with High Sensitivity RNA TapeStation (Agilent, Stockport, UK). Two
endogenous controls were used: miR‐361‐5p and miR‐451a.
Samples were converted to cDNA, and miRNA was amplified using
TaqMan Advanced miRNA cDNA Synthesis Kit (Applied Biosystems,
Thermo Fisher Scientific, Warrington, UK) according to the manufac-
turer's instructions. Reverse transcription polymerase chain reaction
(RT‐PCR) was performed with TaqMan Advanced miRNA Assays
(Applied Biosystems) according to the manufacturer's instructions.
Five microliters of 1:10 dilution of cDNA template was used for the
RT‐PCR reaction with 10 μL of 2× TaqMan Fast Advanced Master
Mix (Applied Biosystems), 1 μL of 20× TaqMan Advanced miRNA
Assay, and 4 μL of RNase‐free water. The reaction was run on the
QuantStudio 5 instrument (Applied Biosystems) under conditions:
one cycle for 20 seconds at 95°C and then 40 cycles of 1 second at
95°C and 20 seconds at 60°C.2.8 | Statistical analysis
Normalization was performed based on the average of the assays
detected in all 10 samples. A heatmap with red denoting miRNA
expression above the mean and green denoting miRNA expression
below the mean, and a principal component analysis (PCA) plot were
drawn to assess the miRNA expression profiles of the samples by
depicting the normalized dCq values for the top 50 miRNAs with the
widest variation in expression in the samples. If any samples appeared
to be outliers, this was further investigated as to whether the cause
was due to pathology, sample quality, an error in processing, or natural
miRNA variation. To compare the miRNAs in different groups, a vol-
cano plot was drawn to allow easy identification of miRNAs upregu-
lated and downregulated in each group. To quantitatively compare
the groups, normality of the data was assessed using the Shapiro‐Wilk
test. The t test was used when data were parametric, and the
Wilcoxon test or Mann‐Whitney U test was used when data were
nonparametric to compare matched samples, or groups accordingly.
If any significant differences were seen, the validated miRNA target
interactions were investigated of the five most significantly upregu-
lated and five most significantly downregulated miRNAs, using
miRTarBase (version 7.0).39 Benjamini‐Hochberg correction was
applied to control for the false discovery rate in the context of multi-
ple testing. P < .05 was considered significant. In order to further
investigate the differential expression differences and correct for pop-
ulation substructure, raw dCt data on a probe‐wise level was imported
into R 3.3.1 (R Core Team (2013). R: A language and environment for
MACKIE ET AL. 619statistical computing (R Foundation for Statistical Computing, Vienna,
Austria)), and multivariate logistic regression analysis was performed
with case control as the outcome and age, ethnicity, gestation, parity,
and maternal BMI as independent variables along with dCt using
limma. Moderated ‐statistics were then calculated using empirical
Bayesian shrinkage (eBayes) and the topTable command used to rank
significant probes by descending Bayes factor (BF).To assess the vali-
dation cohort, individual data points were plotted on Stata using the
dotplot command.40 The ΔΔCts of the control group were compared
with the matched ΔΔCts of the TTTS group by the Wilcoxon signed
rank test on using the signrank command.41 Findings with P < .05 were
considered significant.
For the initial profiling array, no power calculation was performed
as it was discovery work, thus a sample size of 10 is considered ade-
quate, based on existing literature. The results of the investigation
cohort were used to perform a power calculation based on the
observed dCt values, standard deviations and correcting for multiple
testing (using Stata 12.1) and revealed that 16 samples (n = 8 TTTS,
n = 8 control) are needed in the validation cohort to demonstrate a
statistically significant difference between the TTTS and uncompli-
cated MC twin pregnancy samples, with close matching of demo-
graphic variables in subjects, as in the investigation cohort.3 | RESULTS
3.1 | Monochorionic twin pregnancy demographic
data
3.1.1 | Investigation cohort
In the investigation cohort, five patients were included in the TTTS
group and were matched to five from the control group: 2001 was
paired with 2047, 2002 with 2020, 2018 with 2027, 2022 with 2039,
2043 and 2023. TTTS patients were selected pragmatically to repre-
sent different outcomes of TTTS and matched as closely with theTABLE 1 Investigation cohort demographic data
Patient Number
Complication
(Quintero Stage)
Maternal
Age, y
Maternal
Ethnicity
2001 Nil 24 White Europe
2047 TTTS (Stage 2) 29 White Europe
2002 Nil 27 White Europe
2020 TTTS (Stage 3R) 33 White Europe
2018 Nil 24 White Europe
2027 TTTS (Stage 3R) 23 White Europe
2022a Nil 28 White Europe
2039 TTTS (Stage 2) 28 White Europe
2043 Nil 29 White Europe
2023 TTTS (Stage 2) 35 White Europe
Abbreviations: BMI, body mass index; GA, gestational age; TTTS, twin‐twin tra
aThis patient was excluded from analysis as a biological outlier due to natural vcontrol group as possible. There was no significant difference in the
patient demographics of the two groups (Table 1). The median gesta-
tional age at blood sampling in the TTTS group was 20+0 weeks (IQR,
19+4‐20+0 weeks) compared with 20+2 weeks (20‐20+2) in the control
group.3.1.2 | Validation cohort
An independent cohort of 19 women in total was included in the val-
idation cohort. The sample from participant 2124 was used as the ref-
erence sample as it most closely matched the median characteristics of
the validation control group. Samples 2102 and 2013 (TTTS samples)
were removed from analysis as there was insufficient miRNA in the
samples; thus, there were eight control samples and eight TTTS sam-
ples (Table 2); 2015 was paired with 2067, 2045 with 2025, 2068 with
2071, 2094 with 2069, 2104 with 2012, 2108 with 2101, 2112 with
2009, 2086 and 2017. TTTS patients were selected to match the con-
trol group as closely as possible. The median gestational age at blood
sampling in the TTTS group was 20+1 weeks (IQR, 19+6‐20+5 wk)
compared with 20+2 weeks (20+0‐20+6 wk) in the control group.3.1.3 | Quality control of investigation profiling array
samples
There was a low level of hemolysis in all 10 samples, and the steady
level of the spike‐ins in the samples demonstrated high‐quality input
RNA and successful reverse transcription and qPCR (data available
on request). From the heatmap and PCA plot of the top 50 miRNA
with largest variation in expression across all samples (Figures 1 and
2), sample 2022 (control) appeared to be an outlier. When this was
further investigated, the quality of the sample was the same as
the other samples, and there was no clinical reason why this
sample should be different; therefore, the difference was believed to
be due to biological variation, and the sample was excluded from
further analysis.Parity
Maternal
BMI, kg/m2
GA at Blood
Sampling, wk Fetal Sex
an 0 31.9 19+1 Female
an 1 29.4 20+0 Female
an 1 25.2 19+4 Female
an 1 15.8 19+5 Female
an 0 24.7 20+0 Female
an 1 32 20+3 Male
an 0 29.4 20+0 Female
an 0 19.6 20+2 Female
an 0 18.5 21+1 Male
an 0 25.1 20+2 Male
nsfusion syndrome.
ariation in maternal miRNA.
TABLE 2 Validation cohort demographic data
Patient Number
Complication
(Quintero Stage) Maternal Age, y Maternal Ethnicity Parity
Maternal
BMI, kg/m2
GA at Blood
Sampling, wk Fetal Sex
2015 Nil 42 White European 4 44.5 20+0 Female
2067 TTTS (Stage 3) 27 White European 1 35.7 19+4 Female
2045 Nil 20 White European 2 19.0 21+5 Male
2025 TTTS (Stage 2) 22 White European 2 18.3 20+4 Male
2068 Nil 36 White European 1 25.5 19+6 Female
2071 TTTS (Stage 1) 35 White European 1 22.7 20+0 Female
2094 Nil 30 White European 0 27.1 20+3 Female
2069 TTTS (Stage 3) 28 White European 1 23.5 20+1 Female
2104 Nil 36 White European 1 25.6 20+4 Male
2012 TTTS (Stage 3) 27 White European 3 23.5 20+1 Male
2108 Nil 34 White European 0 29.1 19+2 Male
2101 TTTS (Stage 2) 24 White European 1 23.9 21+0 Female
2112 Nil 36 White European 1 24.6 20+0 Male
2009 TTTS (Stage 2) 24 White European 1 27.6 19+4 Male
2086 Nil
2017 TTTS (Stage 3) 28 White European 4 29.8 21+3 Female
2124 (reference) Nil 28 White European 1 31.7 20+2 Female
2102a TTTS (Stage 3) 21 White European 0 28.6 19+1 Male
2013a TTTS (Stage 3) 20 White European 1 19.8 19+5 Female
Abbreviations: BMI, body mass index; GA, gestational age; TTTS, twin‐twin transfusion syndrome.
aPatient excluded from analysis as insufficient miRNA.
FIGURE 1 Heatmap of miRNA expression in all maternal serum
samples from pregnancies with twin‐twin transfusion syndrome
(TTTS) compared with matched controls with uncomplicated
monochorionic diamniotic twin pregnancies [Colour figure can be
viewed at wileyonlinelibrary.com]
620 MACKIE ET AL.3.1.4 | Detection of differential miRNAs in TTTS and
control patients in profiling array samples
A total of 555 of 752 miRNAs were detected; 185 miRNAs were
identified in all samples, with a mean of 313 miRNAs detectable
per sample. In the PCA, there was a trend towards bimodal
clustering of the nine samples (excluding 2022), depending on
whether they were TTTS or control samples, which suggests there
may be a difference between the groups, although there was still
dispersion. The volcano plot demonstrated a number of significantly
different miRNA; some were upregulated and some downregulated
(Figure 3, significantly differentially expressed shown in red, nonsig-
nificant in blue).
Thirty‐one miRNAs were significantly different in the TTTS
compared with control group (see Appendix C for all and Table 3 for
“Top 5”). Seventeen miRNAs were upregulated in the TTTS samples,
in order of statistical significance: hsa‐miR‐107, hsa‐miR‐519c‐3p,
hsa‐let‐7b‐5p, hsa‐miR‐517a‐3p, hsa‐miR‐33a‐3p, hsa‐let‐7c‐5p, hsa‐
miR‐519d‐3p, hsa‐miR‐519a‐3p, hsa‐miR‐30b‐5p, hsa‐miR‐518c‐3p,
hsa‐miR‐26b‐5p, hsa‐miR‐517c‐3p, hsa‐miR‐99a‐5p, hsa‐miR‐20b‐
FIGURE 2 Principal component analysis (PCA) plot of top 50 miRNA
with largest variation in expression across all maternal serum samples
from pregnancies with twin‐twin transfusion syndrome (TTTS)
compared with matched controls with uncomplicated monochorionic
diamniotic twin pregnancies [Colour figure can be viewed at
wileyonlinelibrary.com]
FIGURE 3 Volcano plot comparing fold change of miRNA expression
in maternal serum samples from pregnancies with twin‐twin
transfusion syndrome (TTTS) compared with matched controls with
uncomplicated monochorionic diamniotic twin pregnancies, after
exclusion of one biological outlier. Red denotes miRNAs with
statistically significant fold change difference in TTTS, and blue
denotes miRNAs with no significant difference [Colour figure can be
viewed at wileyonlinelibrary.com]
MACKIE ET AL. 6215p, hsa‐miR‐519b‐3p, hsa‐miR‐144‐3p, and hsa‐miR‐17‐5p; and 14
were downregulated: hsa‐miR‐551a, hsa‐miR‐361‐5p, hsa‐miR‐140‐
5p, hsa‐miR‐9‐5p, hsa‐miR‐135a‐5p, hsa‐miR‐128‐3p, hsa‐miR‐450a‐
5p, hsa‐miR‐582‐3p, hsa‐miR‐26b‐3p, hsa‐miR‐151a‐5p, hsa‐let‐7d‐
3p, hsa‐miR‐556‐3p, hsa‐miR‐223‐3p, and hsa‐miR‐543. They did
not remain significant following the Benjamini‐Hochberg correction
for multiple testing. A Bayesian model technique was used to examine
the differential expression between TTTS and control (Table 4), both
unadjusted and adjusted for maternal age, BMI, ethnicity, parity, and
gestational age at blood sampling. Neither adjusted nor nonadjusted
models demonstrated any significant differential expression between
TTTS and control groups by Bayes factor.3.1.5 | Identification of candidate miRNAs for
validation
Eight miRNAs were identified for validation (Table 5). All miRNAs were
detected in all samples in the investigation cohort. No MTI studies
were found in maternal serum in pregnancy. See Appendix D for more
information on the biological plausibility of the candidate miRNAs.3.1.6 | Validation of candidate miRNAs
There was no significant difference in miRNA expression between the
TTTS group and the control group (Figure 4). It was not possible to
perform RT‐PCR of miR519a‐3p or miR519c‐3p.4 | DISCUSSION
This is the first study to compare human maternal serum miRNAs in
pregnancies complicated with TTTS and with uncomplicated MCDA
twin pregnancies. We found a difference in expression of maternal
serum miRNAs in pregnancies complicated by TTTS in the initial inves-
tigation cohort. Although the significant difference did not remain fol-
lowing statistical correction for multiple testing, the thresholds for
these corrections are naturally conservative, and it was possible our
small sample size was associated with a type II statistical error; thus,
candidate miRNAs were investigated and validated. None of the can-
didate miRNAs were confirmed as being significantly different in the
validation cohort.
The difference between the investigation cohort and validation
cohort may be that the correction for multiple testing was correct,
and the initial investigation cohort was too small to demonstrate a
statistical difference, particularly as the fold change differences were
small. Another reason why the results were not significant is that
maternal circulating miRNA may come from different sources (fetus,
placenta, or maternal endothelium), and the pathophysiology of
TTTS may affect miRNAs from each source differently. The presence
of two fetuses with different clinical features may also affect circu-
lating miRNA differently. It may also be that as we were unable to
recruit pregnancies with TTTS all at the same stage, that miRNA
expression is affected by different stages. In utero intertwin miRNA
TABLE 3 “Top 5” significantly upregulated miRNAs and downregulated miRNAs prior to Benjamini‐Hochberg correction, in pregnancies com-
plicated by twin‐twin transfusion syndrome (TTTS), compared with control of uncomplicated monochorionic diamniotic twin pregnancies
Assay
Average dCq
TTTS (SD)
Average dCq
Control (SD)
ddCq
TTTS—Control
Fold Change
TTTS/Control
t Test
P Value
hsa‐miR‐107 2.581 (−0.305) 1.765 (0.209) 0.816 1.761 .002
hsa‐miR‐519c‐3p −3.212 (0.551) −4.600 (0.373) 1.388 2.618 .003
hsa‐miR‐551a −2.259 (0.560) −1.098 (0.219) −1.160 −2.235 .007
hsa‐let‐7b‐5p 3.219 (0.366) 2.299 (0.409) 0.919 1.891 .012
hsa‐miR‐361‐5p 1.196 (0.175) 1.611 (0.191) −0.416 −1.334 .014
hsa‐miR‐140‐5p 0.493 (0.145) 1.303 (0.359) −0.810 −1.753 .015
hsa‐miR‐9‐5p −6.594 (0.567) −4.768 (0.529) −1.826 −3.545 .015
hsa‐miR‐135a‐5p −6.030 (0.900) −4.501 (0.331) −1.529 −2.886 .016
hsa‐miR‐517a‐3p 0.695 (0.522) −0.228 (0.404) 0.923 1.896 .020
hsa‐miR‐33a‐3p −4.193 (0.483) −5.326 (0.608) 1.133 2.193 .024
TABLE 4 Bayesian model of significant miRNAs in pregnancies complicated by twin‐twin transfusion syndrome, compared with uncomplicated
monochorionic diamniotic twin pregnancies, unadjusted and adjusted for confounding factors
logFC AveExpr t P Value Adj. P Value B
(a) Unadjusted
hsa‐miR‐494‐3p 10.78839 7.202803 5.912049 .000116 .01834 −0.02452
hsa‐miR‐204‐5p 9.935406 6.635394 5.731394 .00015 .01834 −0.15169
hsa‐miR‐520c‐3p 8.480225 4.711236 5.070715 .0004 .01834 −0.66378
hsa‐miR‐411‐5p 9.925229 7.538905 4.817742 .000592 .01834 −0.88045
hsa‐miR‐181a‐2‐3p 10.45718 8.027257 4.742297 .000667 .01834 −0.94735
hsa‐miR‐381‐3p 10.75888 8.367614 4.601182 .000834 .01834 −1.07533
hsa‐miR‐518d‐3p 10.82702 8.443192 4.579189 .000864 .01834 −1.09561
hsa‐miR‐369‐5p 10.26154 7.965421 4.576583 .000868 .01834 −1.09802
hsa‐miR‐517‐5p 10.31679 8.030072 4.552294 .000902 .01834 −1.12054
hsa‐miR‐10a‐5p 10.44629 8.173513 4.503198 .000976 .01834 −1.16638
(b) Adjusteda
hsa‐miR‐379‐5p −186.379 6.396119 −9.89661 .002952 .574946 −4.59509
hsa‐miR‐9‐5p −197.243 7.054207 −9.77597 .003053 .574946 −4.59509
hsa‐let‐7c‐5p −81.7966 7.004665 −7.37649 .006547 .574946 −4.59509
hsa‐miR‐577 205.4049 3.385849 6.465976 .009306 .574946 −4.59509
hsa‐miR‐503‐5p −190.476 6.641287 −5.89464 .011881 .574946 −4.59509
hsa‐miR‐589‐3p 210.6642 7.959102 5.791917 .012443 .574946 −4.59509
hsa‐miR‐365b‐5p −79.0397 2.389523 −5.55616 .013871 .574946 −4.59509
hsa‐miR‐877‐3p −81.4977 2.40734 −5.14132 .016964 .574946 −4.59509
hsa‐miR‐219a‐2‐3p 83.26375 1.219888 5.016209 .018075 .574946 −4.59509
hsa‐miR‐548d‐5p 82.48287 1.208447 4.997538 .018249 .574946 −4.59509
aAdjusted for maternal age, BMI, ethnicity, parity, and gestational age at blood sampling.
622 MACKIE ET AL.differences in fetal circulation have not been described, and practi-
cally and ethically, it would be difficult to obtain individual fetal
blood samples, as an invasive procedure would be required, that
would increase the risk of miscarriage in a clinical scenario that isalready highly morbid. It may also be that changes in miRNA are a
consequence of TTTS, as opposed to a cause of TTTS. Another rea-
son why there may not be a significant difference in miRNA in
maternal serum in TTTS pregnancies is that TTTS is a disease that
TABLE 5 Candidate miRNAs for validation
miRNA
Fold Change in
Investigation
Cohort
Change in TTTS
Maternal Serum
Compared
With Control
Number of Papers
With Strong Evidence
of Functional MTIa
Functional
MTI Target
Genesa
TTTS Biological
Plausibility
hsa‐let‐7b‐5p 1.89 Upregulated 42 34 Upregulated in
congestive
heart failure
hsa‐miR‐17‐5p 1.37 Upregulated 120 80 Associated with
angiogenesis
hsa‐miR‐107 1.76 Upregulated 49 38 Upregulated in congestive
heart failure, same gene
targets as those involved in
preeclampsia and spiral
artery remodeling
hsa‐miR‐140‐5p −1.75 Downregulated 37 30 Downregulated in
congestive heart failure
hsa‐miR‐223‐3p −1.59 Downregulated 64 48 Downregulated in
stages 3 and 4
chronic kidney disease
hsa‐miR‐517a‐3p 1.90 Upregulated 2 2 Placenta‐specific miRNA
hsa‐miR‐519a‐3p 2.48 Upregulated 12 9 Placenta‐specific miRNA
hsa‐miR‐519c‐3p 2.62 Upregulated 8 6 Placenta‐specific miRNA
Abbreviation: MTI, microRNA‐target interaction.
aAccording to miRTarBase (Chou C, Shrestha S, Yang C, et al. miRTarBase update 2018: a resource for experimentally validated microRNA‐target interac-
tions. Nucleic Acids Res. 2018;46(D1):D296‐302).
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uterine symptoms, such as maternal proteinuria and hypertension
as seen in preeclampsia; therefore, miRNA changes in TTTS may
not be seen in maternal circulation. It is interesting to note that
while miRNA changes are seen in both maternal plasma and placen-
tal tissue in conditions that clinically affect both the mother and the
fetus, such as gestational diabetes,42,43 and preeclampsia,27 in condi-
tions that only affect the fetus, such as fetal growth restriction
(FGR), it is not as clear. Studies by Hromadnikova et al have found
conflicting changes in miRNA in maternal plasma from FGR pregnan-
cies, with miRNA differences apparent at 12 to 16 weeks' gesta-
tion,31 but not at 10 to 13 weeks,44 thus suggesting miRNA may
be gestation dependent. One study looking at miRNA in placental
tissue from FGR pregnancies found significant differences,17 but
another study that compared placental tissue and maternal plasma
from the same FGR pregnancies demonstrated changes in placental
tissue, but not matched maternal plasma,16 despite miRNAs being
able to cross into the maternal circulation. It would be interesting
to examine miRNA expression in placentas of pregnancies compli-
cated by TTTS; however, there would be major confounders in such
a study with many pregnancies having received treatment by FLA
that may alter miRNA expression.
A recent study compared miRNA expression in placental samples
taken from each twin's umbilical cord root insertion, within
monochorionic twin sets in which one twin had FGR and the other
twin was normally grown.13 This was performed as althoughmonochorionic placentation involves a single placenta, there are dif-
fering “vascular territories” between the two fetuses, and this may
vary considerably depending upon the severity of the FGR.45 Wen
et al identified 14 differentially expressed miRNAs (seven upregu-
lated and seven downregulated) in the placental samples of the
larger twin compared with smaller twin. These 14 miRNAs were
not significantly different between the two normally grown twins
in the one monochorionic twin pregnancy, which acted as their con-
trol for the miRNA profiling. All 14 miRNAs were successfully vali-
dated in a separate unmatched cohort (15 monochorionic twin
pregnancies with FGR and 15 monochorionic twin pregnancies with
appropriately grown fetuses). Unfortunately, Wen et al did not col-
lect the respective maternal samples to compare with the miRNA
expression in the placental samples, but the findings suggest that
intertwin differences exist in monochorionic placentas, although this
has not been explored in TTTS placentas. It would be interesting to
examine miRNAs in maternal blood from sIUGR, particularly those
with concurrent TTTS.
It was not possible to perform validation RT‐PCR of the placenta‐
specific miRNA, ie, miRNA that are expressed exclusively in the pla-
centa, for reasons which are not clear, although one possible reason
is the relative low abundance of placenta‐specific miRNA in maternal
serum. As TTTS is a disease that affects the placenta, it may be pos-
sible to validate the array findings in these miRNA.
One strength of our study is that the demographics of our
patient groups were closely matched, which is vital in miRNA
FIGURE 4 Validation of candidate miRNAs. No significant difference between groups (n = 8 controls, and n = 8 TTTS pregnancies) (Wilcoxon
signed‐rank test). Line represents median. miR‐451a used as reference
624 MACKIE ET AL.research,46 and there was good technical performance in our profil-
ing experiment as demonstrated by the RNA spike‐in and no tem-
plate control. Unfortunately, the sample size did not allow us to
look at the impact of other factors such as pregnancy outcome fol-
lowing TTTS, maternal age, BMI, parity, and fetal sex on miRNA in
TTTS, which may have provided further information, although we
did produce a Bayesian model to adjust for these factors and
attempted to match the samples as closely as possible. Due to the
high risk nature of MCDA twins, we were unable to find a group
of control MCDA patients with no comorbidities; therefore, we took
a pragmatic approach and included two patients with comorbidities
(isolated polyhydramnios in one twin at 34 weeks [maximum pool
depth, 8.9 cm], pregnancy‐induced hypertension at 34 weeks), which
we do not believe will have affected the study results as they are
unrelated to TTTS.5 | CONCLUSION
This is the first study to look at miRNAs in maternal serum from
pregnancies complicated by TTTS. Although the initial profiling array
demonstrated a difference in miRNAs in pregnancies complicated by
TTTS compared with control MCDA pregnancies, these finding were
not confirmed in the validation cohort, although it was not possible
to look at the C19MC placenta‐specific miRNA group. Further investi-
gation using alternative biofluids, particularly placental tissue samples,
would be interesting, but pragmatically difficult to obtain.ACKNOWLEDGEMENT
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ADDITIONAL METHODSRNA extractionSerum was thawed on ice to room temperature and centrifuged at 3000 g for 5 minutes; 200 μL of supernatant from each sample was transferred to
new tubes, and 62.5 μL of a well‐mixed master mix of Lysis buffer (60 μL), RNA Spike‐in template mixture (1 μL) (miRCURY LNA Universal RT
microRNA PCR, RNA Spike‐in kit [Exiqon]), and carrier‐RNA (1.5 μL) (MS2 RNA, [Roche, West Sussex, UK]) was added. The samples were vortexed
and incubated for 3 minutes at room temperature. The Protein Precipitation Solution BF (20 μL) was added to each sample, and the samples were
vortexed and incubated for 1 minute at room temperature and then centrifuged at 11 000 g for 3 minutes. The clear supernatant was then transferred
to a new tube and isopropanol (270 μL) was added, and the sample vortexed to adjust the binding conditions. A miRNA Mini Spin Column BF was
placed in a collection tube and the sample loaded onto the column, incubated for 2 minutes at room temperature and centrifuged at 11 000 g for
30 seconds. The flow‐through was discarded and the column placed back in the collection tube. To remove residual DNA that may affect downstream
applications, Wash Solution 2 BF (700 μL) was added to the spin column BF and centrifuged at 11 000 g for 30 seconds. The flow‐through was
discarded and the column returned to the collection tube. This was repeated with 250‐μL Wash Solution 2 and was centrifuged at 11 000 g for
2 minutes. rDNase (50 μL) was added to the membrane of the spin column and incubated for 15 minutes at room temperature to aid digestion of
the DNA. The columns were washed with Wash Solution 1 BF (100 μL), then Wash Solution 2 BF (700 μL), and then Wash Solution 2 BF (250 μL).
Following each wash, the samples were centrifuged at 11 000 g for 30 seconds, apart from the final wash following that the samples were centrifuged
for 2 minutes, to ensure complete drying of the membrane. The spin column was placed in a new collection tube, and RNase free H2O (50 μL) was
added directly onto the membrane, incubated for 1 minute at room temperature, and centrifuged at 11 000 g for 1 minute to elute the samples.APPENDIX B
miRNAs TESTED IN THIS STUDY
hsa‐miR‐107
hsa‐let‐7b‐5p
hsa‐miR‐30b‐5p
hsa‐miR‐26b‐5p
hsa‐let‐7c‐5p
hsa‐miR‐582‐3p
hsa‐miR‐9‐5p
hsa‐miR‐135a‐5p
hsa‐miR‐519d‐3p
hsa‐miR‐556‐3p
hsa‐miR‐517c‐3p
hsa‐miR‐197‐3p
hsa‐miR‐33a‐3p
hsa‐miR‐361‐5p
hsa‐miR‐517a‐3p
hsa‐miR‐17‐5p
hsa‐miR‐223‐3p
hsa‐miR‐144‐3p
hsa‐let‐7d‐3p
hsa‐miR‐519a‐3p
hsa‐miR‐140‐5p
hsa‐miR‐140‐3p
hsa‐miR‐518c‐3p
hsa‐miR‐501‐3p
hsa‐miR‐519b‐3p
hsa‐miR‐629‐5p
hsa‐miR‐20b‐5p
hsa‐miR‐28‐3p
hsa‐miR‐543hsa‐miR‐625‐3p
hsa‐miR‐335‐3p
hsa‐miR‐194‐5p
hsa‐miR‐432‐5p
hsa‐miR‐525‐5p
hsa‐miR‐193a‐5p
hsa‐miR‐146a‐5p
hsa‐miR‐26b‐3p
hsa‐miR‐340‐5p
hsa‐miR‐130a‐3p
hsa‐miR‐15a‐3p
hsa‐miR‐1296‐5p
hsa‐miR‐502‐3p
hsa‐miR‐491‐5p
hsa‐miR‐345‐5p
hsa‐miR‐501‐5p
hsa‐miR‐1249
hsa‐miR‐339‐5p
hsa‐let‐7i‐5p
hsa‐miR‐191‐5p
hsa‐miR‐769‐5p
hsa‐miR‐484
hsa‐miR‐1271‐5p
hsa‐miR‐21‐5p
hsa‐miR‐582‐5p
hsa‐miR‐493‐3p
hsa‐miR‐431‐5p
hsa‐miR‐30e‐3p
hsa‐miR‐99a‐5p
hsa‐miR‐181a‐5p
hsa‐miR‐146b‐5p
hsa‐miR‐362‐3p
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hsa‐miR‐126‐5p
hsa‐miR‐93‐3p
hsa‐miR‐101‐3p
hsa‐miR‐378a‐5p
hsa‐miR‐101‐5p
hsa‐miR‐532‐3p
hsa‐miR‐139‐3p
hsa‐miR‐628‐3p
hsa‐miR‐15b‐5p
hsa‐miR‐376a‐3p
hsa‐miR‐519c‐3p
hsa‐miR‐505‐5p
hsa‐miR‐126‐3p
hsa‐miR‐15b‐3p
hsa‐let‐7f‐2‐3p
hsa‐miR‐33a‐5p
hsa‐miR‐342‐3p
hsa‐miR‐337‐5p
hsa‐miR‐518f‐3p
hsa‐miR‐223‐5p
hsa‐miR‐339‐3p
hsa‐miR‐152‐3p
hsa‐miR‐940
hsa‐miR‐148b‐5p
hsa‐miR‐660‐5p
hsa‐miR‐424‐5p
hsa‐miR‐186‐5p
hsa‐miR‐103a‐3p
hsa‐miR‐125a‐5p
hsa‐miR‐155‐5p
hsa‐miR‐218‐5p
hsa‐miR‐331‐3p
hsa‐miR‐329‐3p
hsa‐let‐7b‐3p
hsa‐miR‐1
hsa‐miR‐335‐5p
hsa‐miR‐127‐3p
hsa‐let‐7g‐3p
hsa‐miR‐509‐3p
hsa‐miR‐518b
hsa‐miR‐551a
hsa‐miR‐515‐3p
hsa‐miR‐598‐3p
hsa‐miR‐196b‐5p
hsa‐miR‐1537‐3p
hsa‐miR‐24‐3p
hsa‐miR‐214‐3p
hsa‐miR‐454‐3p
hsa‐miR‐525‐3p
hsa‐miR‐365a‐3p
hsa‐miR‐148a‐3p
hsa‐miR‐324‐3phsa‐miR‐320b
hsa‐miR‐520h
hsa‐miR‐2110
hsa‐miR‐320d
hsa‐miR‐142‐3p
hsa‐miR‐377‐3p
hsa‐miR‐515‐5p
hsa‐miR‐379‐5p
hsa‐miR‐96‐5p
hsa‐miR‐32‐5p
hsa‐miR‐627‐5p
hsa‐miR‐27b‐3p
hsa‐miR‐153‐3p
hsa‐miR‐145‐3p
hsa‐miR‐16‐2‐3p
hsa‐miR‐664a‐3p
hsa‐miR‐542‐5p
hsa‐miR‐618
hsa‐miR‐26a‐5p
hsa‐miR‐550a‐3p
hsa‐miR‐16‐5p
hsa‐miR‐99b‐5p
hsa‐miR‐520a‐5p
hsa‐miR‐450b‐5p
hsa‐miR‐520g‐3p
hsa‐miR‐122‐3p
hsa‐miR‐143‐3p
hsa‐miR‐425‐3p
hsa‐miR‐25‐3p
hsa‐let‐7f‐5p
hsa‐miR‐376a‐5p
hsa‐miR‐30e‐5p
hsa‐miR‐326
hsa‐miR‐376b‐3p
hsa‐miR‐328‐3p
hsa‐miR‐106b‐5p
hsa‐miR‐744‐5p
hsa‐miR‐624‐5p
hsa‐miR‐518c‐5p
hsa‐miR‐370‐3p
hsa‐miR‐524‐5p
hsa‐miR‐106b‐3p
hsa‐let‐7g‐5p
hsa‐miR‐10a‐5p
hsa‐miR‐19b‐1‐5p
hsa‐miR‐106a‐5p
hsa‐miR‐574‐3p
hsa‐miR‐144‐5p
hsa‐miR‐889‐3p
hsa‐miR‐203a
hsa‐miR‐1260a
hsa‐miR‐320a
hsa‐miR‐7‐1‐3p
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hsa‐miR‐519e‐3p
hsa‐miR‐30a‐3p
hsa‐miR‐128‐3p
hsa‐miR‐425‐5p
hsa‐miR‐19b‐3p
hsa‐miR‐337‐3p
hsa‐miR‐125b‐5p
hsa‐miR‐221‐5p
hsa‐miR‐132‐3p
hsa‐miR‐502‐5p
hsa‐miR‐654‐5p
hsa‐miR‐188‐3p
hsa‐miR‐30a‐5p
hsa‐miR‐141‐3p
hsa‐miR‐496
hsa‐miR‐20a‐5p
hsa‐miR‐1972
hsa‐miR‐423‐3p
hsa‐miR‐526b‐5p
hsa‐let‐7d‐5p
hsa‐miR‐584‐5p
hsa‐miR‐579‐3p
hsa‐miR‐518e‐5p
hsa‐miR‐301a‐3p
hsa‐miR‐182‐5p
hsa‐miR‐151a‐5p
hsa‐miR‐29a‐5p
hsa‐miR‐224‐5p
hsa‐miR‐143‐5p
hsa‐miR‐23b‐3p
hsa‐miR‐185‐5p
hsa‐miR‐548j‐5p
hsa‐miR‐215‐5p
hsa‐miR‐450a‐5p
hsa‐miR‐22‐3p
hsa‐miR‐100‐5p
hsa‐miR‐29b‐3p
hsa‐miR‐512‐3p
hsa‐miR‐874‐3p
hsa‐miR‐518f‐5p
hsa‐miR‐942‐5p
hsa‐miR‐409‐3p
hsa‐let‐7a‐5p
hsa‐let‐7f‐1‐3p
hsa‐miR‐324‐5p
hsa‐miR‐548k
hsa‐miR‐487b‐3p
hsa‐miR‐16‐1‐3p
hsa‐miR‐154‐5p
hsa‐miR‐524‐3p
hsa‐miR‐195‐5p
hsa‐miR‐654‐3phsa‐miR‐205‐5p
hsa‐miR‐24‐2‐5p
hsa‐miR‐199a‐3p
hsa‐miR‐423‐5p
hsa‐miR‐342‐5p
hsa‐miR‐374b‐5p
hsa‐miR‐675‐3p
hsa‐miR‐18b‐5p
hsa‐miR‐21‐3p
hsa‐miR‐505‐3p
hsa‐miR‐30d‐5p
hsa‐miR‐486‐3p
hsa‐miR‐539‐5p
hsa‐miR‐532‐5p
hsa‐miR‐22‐5p
hsa‐miR‐145‐5p
hsa‐miR‐296‐5p
hsa‐miR‐483‐3p
hsa‐miR‐130b‐5p
hsa‐miR‐142‐5p
hsa‐miR‐139‐5p
hsa‐miR‐330‐3p
hsa‐miR‐495‐3p
hsa‐miR‐10b‐5p
hsa‐miR‐518e‐3p
hsa‐miR‐192‐5p
hsa‐miR‐148b‐3p
hsa‐miR‐320c
hsa‐miR‐369‐3p
hsa‐miR‐181b‐5p
hsa‐miR‐545‐3p
hsa‐miR‐34a‐3p
hsa‐miR‐628‐5p
hsa‐miR‐27a‐5p
hsa‐miR‐133b
hsa‐miR‐181c‐3p
hsa‐miR‐375
hsa‐miR‐522‐3p
hsa‐miR‐188‐5p
hsa‐miR‐93‐5p
hsa‐miR‐18a‐3p
hsa‐miR‐766‐3p
hsa‐miR‐210‐3p
hsa‐miR‐376c‐3p
hsa‐let‐7i‐3p
hsa‐miR‐19a‐3p
hsa‐miR‐122‐5p
hsa‐miR‐29c‐3p
hsa‐miR‐652‐3p
hsa‐miR‐382‐5p
hsa‐miR‐33b‐5p
hsa‐miR‐548c‐5p
hsa‐miR‐338‐3p
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hsa‐miR‐493‐5p
hsa‐miR‐136‐5p
hsa‐miR‐222‐3p
hsa‐miR‐200b‐3p
hsa‐miR‐193a‐3p
hsa‐miR‐133a‐3p
hsa‐miR‐301b
hsa‐miR‐451a
hsa‐miR‐18a‐5p
hsa‐miR‐95‐3p
hsa‐miR‐424‐3p
hsa‐miR‐23a‐3p
hsa‐miR‐15a‐5p
hsa‐miR‐150‐5p
hsa‐miR‐34a‐5p
hsa‐miR‐27a‐3p
hsa‐miR‐323a‐3p
hsa‐miR‐219a‐5p
hsa‐miR‐193b‐3p
hsa‐miR‐151a‐3p
hsa‐miR‐29c‐5p
hsa‐miR‐181c‐5p
hsa‐miR‐421
hsa‐miR‐29a‐3p
hsa‐miR‐483‐5p
hsa‐miR‐363‐3p
mmu‐miR‐378a‐3p
hsa‐miR‐134‐5p
hsa‐miR‐409‐5p
hsa‐miR‐17‐3p
hsa‐miR‐98‐5p
hsa‐miR‐518a‐3p
hsa‐miR‐190a‐5p
hsa‐miR‐589‐3p
hsa‐miR‐576‐5p
hsa‐miR‐486‐5p
hsa‐miR‐7‐5p
hsa‐miR‐199b‐5p
hsa‐miR‐518d‐5p
hsa‐miR‐183‐5p
hsa‐miR‐551b‐3p
hsa‐miR‐452‐5p
hsa‐miR‐200c‐3p
hsa‐miR‐130b‐3p
hsa‐miR‐877‐5p
hsa‐miR‐485‐3p
hsa‐miR‐30d‐3p
hsa‐miR‐20a‐3p
hsa‐miR‐199a‐5p
hsa‐miR‐548a‐3p
hsa‐miR‐340‐3p
hsa‐miR‐651‐5phsa‐miR‐92a‐3p
hsa‐miR‐519e‐5p
hsa‐miR‐374a‐5p
hsa‐miR‐28‐5p
hsa‐miR‐590‐5p
hsa‐miR‐29b‐2‐5p
hsa‐miR‐497‐5p
hsa‐miR‐221‐3p
hsa‐miR‐30c‐5p
hsa‐miR‐410‐3p
hsa‐let‐7e‐5p
hsa‐miR‐516b‐5p
hsa‐miR‐744‐3p
hsa‐miR‐590‐3p
hsa‐miR‐361‐3p
hsa‐let‐7a‐3p
hsa‐let‐7e‐3p
hsa‐miR‐106a‐3p
hsa‐miR‐10a‐3p
hsa‐miR‐10b‐3p
hsa‐miR‐1178‐3p
hsa‐miR‐1181
hsa‐miR‐1183
hsa‐miR‐1185‐5p
hsa‐miR‐1205
hsa‐miR‐1207‐5p
hsa‐miR‐1224‐3p
hsa‐miR‐1227‐3p
hsa‐miR‐1237‐3p
hsa‐miR‐1243
hsa‐miR‐124‐3p
hsa‐miR‐1244
hsa‐miR‐1247‐5p
hsa‐miR‐1253
hsa‐miR‐1254
hsa‐miR‐1255b‐5p
hsa‐miR‐1256
hsa‐miR‐1258
hsa‐miR‐125a‐3p
hsa‐miR‐125b‐2‐3p
hsa‐miR‐1269a
hsa‐miR‐1270
hsa‐miR‐127‐5p
hsa‐miR‐135a‐3p
hsa‐miR‐135b‐5p
hsa‐miR‐137
hsa‐miR‐138‐5p
hsa‐miR‐1468‐5p
hsa‐miR‐146a‐3p
hsa‐miR‐146b‐3p
hsa‐miR‐1471
hsa‐miR‐149‐5p
hsa‐miR‐1538
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hsa‐miR‐181a‐2‐3p
hsa‐miR‐181a‐3p
hsa‐miR‐181d‐5p
hsa‐miR‐182‐3p
hsa‐miR‐184
hsa‐miR‐185‐3p
hsa‐miR‐187‐3p
hsa‐miR‐18b‐3p
hsa‐miR‐1908‐5p
hsa‐miR‐190b
hsa‐miR‐1911‐5p
hsa‐miR‐1912
hsa‐miR‐1913
hsa‐miR‐191‐3p
hsa‐miR‐192‐3p
hsa‐miR‐193b‐5p
hsa‐miR‐194‐3p
hsa‐miR‐195‐3p
hsa‐miR‐196a‐5p
hsa‐miR‐196b‐3p
hsa‐miR‐198
hsa‐miR‐19a‐5p
hsa‐miR‐200a‐3p
hsa‐miR‐200b‐5p
hsa‐miR‐204‐5p
hsa‐miR‐206
hsa‐miR‐208b‐3p
hsa‐miR‐20b‐3p
hsa‐miR‐2113
hsa‐miR‐211‐5p
hsa‐miR‐212‐3p
hsa‐miR‐214‐5p
hsa‐miR‐216a‐5p
hsa‐miR‐219a‐2‐3p
hsa‐miR‐224‐3p
hsa‐miR‐23a‐5p
hsa‐miR‐23b‐5p
hsa‐miR‐24‐1‐5p
hsa‐miR‐25‐5p
hsa‐miR‐26a‐1‐3p
hsa‐miR‐26a‐2‐3p
hsa‐miR‐27b‐5p
hsa‐miR‐296‐3p
hsa‐miR‐299‐3p
hsa‐miR‐299‐5p
hsa‐miR‐300
hsa‐miR‐302d‐5p
hsa‐miR‐31‐3p
hsa‐miR‐31‐5p
hsa‐miR‐32‐3p
hsa‐miR‐330‐5p
hsa‐miR‐331‐5phsa‐miR‐338‐5p
hsa‐miR‐33b‐3p
hsa‐miR‐346
hsa‐miR‐34b‐5p
hsa‐miR‐34c‐5p
hsa‐miR‐362‐5p
hsa‐miR‐365b‐5p
hsa‐miR‐369‐5p
hsa‐miR‐371a‐3p
hsa‐miR‐373‐3p
hsa‐miR‐373‐5p
hsa‐miR‐374b‐3p
hsa‐miR‐379‐3p
hsa‐miR‐380‐3p
hsa‐miR‐380‐5p
hsa‐miR‐381‐3p
hsa‐miR‐382‐3p
hsa‐miR‐411‐3p
hsa‐miR‐411‐5p
hsa‐miR‐429
hsa‐miR‐431‐3p
hsa‐miR‐433‐3p
hsa‐miR‐449a
hsa‐miR‐449b‐3p
hsa‐miR‐450b‐3p
hsa‐miR‐454‐5p
hsa‐miR‐455‐3p
hsa‐miR‐487a‐3p
hsa‐miR‐491‐3p
hsa‐miR‐494‐3p
hsa‐miR‐498
hsa‐miR‐499a‐5p
hsa‐miR‐500a‐5p
hsa‐miR‐503‐5p
hsa‐miR‐504‐5p
hsa‐miR‐511‐5p
hsa‐miR‐512‐5p
hsa‐miR‐514a‐3p
hsa‐miR‐516a‐3p
hsa‐miR‐516a‐5p
hsa‐miR‐517‐5p
hsa‐miR‐518d‐3p
hsa‐miR‐520a‐3p
hsa‐miR‐520c‐3p
hsa‐miR‐520d‐3p
hsa‐miR‐520d‐5p
hsa‐miR‐520e
hsa‐miR‐521
hsa‐miR‐523‐3p
hsa‐miR‐544a
hsa‐miR‐548a‐5p
hsa‐miR‐548b‐3p
hsa‐miR‐548d‐5p
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hsa‐miR‐548i
hsa‐miR‐548l
hsa‐miR‐548n
hsa‐miR‐550a‐5p
hsa‐miR‐552‐3p
hsa‐miR‐566
hsa‐miR‐567
hsa‐miR‐570‐3p
hsa‐miR‐571
hsa‐miR‐576‐3p
hsa‐miR‐577
hsa‐miR‐589‐5p
hsa‐miR‐592
hsa‐miR‐593‐3p
hsa‐miR‐595
hsa‐miR‐596
hsa‐miR‐601
hsa‐miR‐604
hsa‐miR‐605‐5p
hsa‐miR‐609
hsa‐miR‐610
hsa‐miR‐615‐3p
hsa‐miR‐616‐3p
hsa‐miR‐616‐5p
hsa‐miR‐619‐3p
hsa‐miR‐623
hsa‐miR‐629‐3p
hsa‐miR‐631
hsa‐miR‐635
hsa‐miR‐640
hsa‐miR‐642a‐5p
hsa‐miR‐643
hsa‐miR‐645
hsa‐miR‐646Assay
Average dCq
TTTS (SD)
Average dCq
Control (SD)
dd
Co
hsa‐miR‐107 2.581 (−0.305) 1.765 (0.209)
hsa‐miR‐519c‐3p −3.212 (0.551) −4.600 (0.373)
hsa‐miR‐551a −2.259 (0.560) −1.098 (0.219)
hsa‐let‐7b‐5p 3.219 (0.366) 2.299 (0.409)
hsa‐miR‐361‐5p 1.196 (0.175) 1.611 (0.191)
hsa‐miR‐140‐5p 0.493 (0.145) 1.303 (0.359)hsa‐miR‐649
hsa‐miR‐650
hsa‐miR‐655‐3p
hsa‐miR‐661
hsa‐miR‐662
hsa‐miR‐663a
hsa‐miR‐663b
hsa‐miR‐668‐3p
hsa‐miR‐671‐3p
hsa‐miR‐671‐5p
hsa‐miR‐708‐3p
hsa‐miR‐708‐5p
hsa‐miR‐758‐3p
hsa‐miR‐760
hsa‐miR‐761
hsa‐miR‐765
hsa‐miR‐769‐3p
hsa‐miR‐770‐5p
hsa‐miR‐873‐5p
hsa‐miR‐875‐5p
hsa‐miR‐876‐5p
hsa‐miR‐877‐3p
hsa‐miR‐885‐3p
hsa‐miR‐887‐3p
hsa‐miR‐922
hsa‐miR‐92a‐1‐5p
hsa‐miR‐92b‐3p
hsa‐miR‐92b‐5p
hsa‐miR‐933
hsa‐miR‐934
hsa‐miR‐936
hsa‐miR‐937‐3p
hsa‐miR‐9‐3p
hsa‐miR‐99a‐3p
hsa‐miR‐99b‐3pAPPENDIX C
SIGNIFICANTLY DIFFERENT miRNAs, PRIOR TO BENJAMINI‐HOCHBERG CORRECTION, IN
PREGNANCIES COMPLICATED BY TWIN‐TWIN TRANSFUSION SYNDROME, COMPARED WITH
UNCOMPLICATED MCDA PREGNANCIESCq TTTS—
ntrol
Fold Change
TTTS/Control
t Test
P Value
Benjamini‐
Hochberg FDR
0.816 1.761 .002 0.486
1.388 2.618 .003 0.486
−1.160 −2.235 .007 0.494
0.919 1.891 .012 0.494
−0.416 −1.334 .014 0.494
−0.810 −1.753 .015 0.494
(Continued)
Assay
Average dCq
TTTS (SD)
Average dCq
Control (SD)
ddCq TTTS—
Control
Fold Change
TTTS/Control
t Test
P Value
Benjamini‐
Hochberg FDR
hsa‐miR‐9‐5p −6.594 (0.567) −4.768 (0.529) −1.826 −3.545 .015 0.494
hsa‐miR‐135a‐5p −6.030 (0.900) −4.501 (0.331) −1.529 −2.886 .016 0.494
hsa‐miR‐517a‐3p 0.695 (0.522) −0.228 (0.404) 0.923 1.896 .020 0.494
hsa‐miR‐33a‐3p −4.193 (0.483) −5.326 (0.608) 1.133 2.193 .024 0.494
hsa‐let‐7c‐5p −0.032 (0.516) −0.856 (0.361) 0.823 1.769 .026 0.494
hsa‐miR‐519d‐3p −0.868 (0.635) −2.246 (0.770) 1.377 2.598 .029 0.494
hsa‐miR‐128‐3p −1.117 (0.250) −0.460 (0.376) −0.656 −1.576 .030 0.494
hsa‐miR‐519a‐3p −2.319 (0.743) −3.632 (0.697) 1.313 2.484 .031 0.494
hsa‐miR‐30b‐5p 2.585 (0.147) 1.908 (0.383) 0.677 1.599 .032 0.494
hsa‐miR‐518c‐3p −2.275 (1.176) −3.958 (0.499) 1.683 3.211 .033 0.494
hsa‐miR‐26b‐5p 0.995 (0.578) −0.262 (0.736) 1.257 2.390 .033 0.494
hsa‐miR‐517c‐3p −0.793 (0.602) −1.828 (0.562) 1.035 2.048 .034 0.494
hsa‐miR‐450a‐5p −1.175 (0.684) −0.224 (0.160) −0.950 −1.932 .034 0.494
hsa‐miR‐582‐3p −3.722 (0.977) −2.096 (0.877) −1.627 −3.088 .035 0.494
hsa‐miR‐99a‐5p −0.643 (0.421) −1.375 (0.411) 0.732 1.661 .036 0.494
hsa‐miR‐26b‐3p −4.091 (0.689) −2.986 (0.609) −1.105 −2.151 .039 0.494
hsa‐miR‐151a‐5p 1.935 (0.193) 2.300 (0.219) −0.365 −1.288 .039 0.494
hsa‐let‐7d‐3p 2.093 (0.480) 2.724 (0.169) −0.630 −1.548 .040 0.494
hsa‐miR‐20b‐5p −4.324 (0.561) −6.309 (1.228) 1.985 3.958 .040 0.494
hsa‐miR‐519b‐3p −4.841 (0.552) −6.357 (0.707) 1.516 2.859 .041 0.494
hsa‐miR‐556‐3p −5.746 (0.547) −4.483 (0.489) −1.262 −2.399 .041 0.494
hsa‐miR‐144‐3p 6.066 (0.566) 5.028 (0.637) 1.039 2.054 .042 0.494
hsa‐miR‐223‐3p 9.903 (0.437) 10.570 (0.373) −0.667 −1.588 .043 0.494
hsa‐miR‐17‐5p −1.374 (0.353) −1.832 (0.196) 0.457 1.373 .047 0.515
hsa‐miR‐543 −2.876 (0.797) −1.899 (0.293) −0.976 −1.967 .050 0.526
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BIOLOGICAL PLAUSIBILITY OF THE CANDIDATE miRNAs
ThemiRNAs inwhich a differencewas revealed inTTTS pregnancies in the investigation cohort may reflect overlapping clinical features often seen in
the disease process. Up to 70% of recipient twins have associated cardiac right ventricular dysfunction47; interestingly, in adults with congestive
heart failure, circulating hsa‐miR‐140‐5p is reported as being downregulated, and hsa‐miR‐107 and hsa‐let‐7b‐5p appears upregulated,48 which is
what was found inTTTS patients in the investigation cohort. TTTS is also associated with significant changes in renal physiology in both the donor
and recipient.49-51 Circulating hsa‐miR‐223‐3p has been found to be downregulated in adults with chronic kidney disease (stages 4 and 5) (Ulbing,
2017), again echoing the findings in theTTTS investigation cohort.
Approximately 60% of TTTS pregnancies are also affected by fetal growth restriction (FGR),52 and changes have been demonstrated in miRNA
in placental tissue from FGR singleton pregnancies, although there was no overlap with the miRNA changes demonstrated in the maternal serum
samples from the investigation cohort.53 However, another study compared placental tissue and maternal plasma from FGR pregnancies and dem-
onstrated changes in placental tissue, but not maternal plasma, despite miRNAs being able to cross into the maternal circulation.54 A recent study
compared miRNA expression in placental samples taken from each twin's umbilical cord root insertion, within monochorionic twinsets in which
one twin had FGR, and the other twin was normally grown.55 This was performed as although monochorionic placentation involves a single pla-
centa, there is differing “vascular territories” between the two fetuses, and this may vary considerably depending upon the severity of the FGR.56
Wen et al identified 14 differentially expressed miRNAs (seven upregulated and seven downregulated) in the placental samples of the larger twin
compared with smaller twin. These 14 miRNAs were not significantly different between the two normally grown twins in the one monochorionic
twin pregnancy, which acted as their control for the miRNA profiling. All 14 miRNAs were successfully validated in a separate unmatched cohort
(15 monochorionic twin pregnancies with FGR and 15 monochorionic twin pregnancies with appropriately grown fetuses). Unfortunately, Wen
634 MACKIE ET AL.et al did not collect the respective maternal blood samples to compare with the miRNA expression in the placental samples, although there was an
overlap with four miRNAs that were significantly different inTTTS pregnancies in the investigation cohort: hsa‐let‐7c, hsa‐miR‐518c‐3p, hsa‐miR‐
144‐3p, and hsa‐miR‐543. hsa‐let‐7c was upregulated in TTTS pregnancies in the investigation cohort and upregulated in the larger twin in Wen
study; however, the changes in the other three miRNAs were in line with the smaller twin, not the larger twin: hsa‐miR‐518c‐3p and hsa‐miR‐144‐
3p were upregulated inTTTS and upregulated in the smaller twin, and hsa‐miR‐543 was downregulated in TTTS and downregulated in the smaller
twin, indicating that an association may exist between miRNA expression in placental samples and maternal serum and TTTS and FGR.
Changes were also demonstrated in the investigation cohort in hsa‐miR‐517a‐3p, hsa‐miR‐519a‐3p, and hsa‐miR‐519c‐3p, which are members
of the C19MC group of placenta‐specific miRNAs,57,58 and are detectable from the first trimester in chorionic villi stromal cells.59 hsa‐miR‐17‐5p is
known to be associated with angiogenesis60 and increased hsa‐miR‐17 and hsa‐miR‐20b expression with reduced spiral artery remodeling61 and
preeclampsia.62 A recent study has found that downregulation of hsa‐miR‐17‐5p improves cardiac function after myocardial infarction, thought to
be due to aiding repair of vascular injury, and decreasing the rate of apoptosis.63 Other miRNAs that were significant prior to correction for mul-
tiple testing have also been demonstrated to be significantly different in maternal serum from singleton pregnancies complicated by preeclampsia:
hsa‐miR‐107, hsa‐miR‐223, hsa‐miR‐26b, hsa‐miR‐30b, hsa‐miR‐517c, hsa‐miR518c, hsa‐miR‐519d, and hsa‐miR‐99a.64,65 This again fits with
issues of placentation and abnormal placental vasculogenesis seen in TTTS, although the majority of this work has been performed in singleton
pregnancies.
With regard to potential gene targets of the differentially expressed miRNA in the investigation cohort identified from miRTarBase, although
there is a paucity of gene target validation studies in pregnancy, the potential gene targets do have biological plausibility, for example, miR‐107
targets include NOTCH2 and DICER1, which have been shown to be involved in preeclampsia and spiral artery remodeling,66,67 which supports
further investigation of these miRNAs in pregnancy to both to improve knowledge of the pathophysiology of TTTS and also to enable further
study of miRNAs as potential biomarkers of TTTS.
